培美曲塞联合顺铂治疗晚期尿路上皮癌的疗效与安全性研究

目的:评估培美曲塞联合顺铂治疗晚期尿路上皮癌的有效性和安全性。方法:纳入在我院泌尿科治疗的65例晚期上皮癌患者。每隔3周为患者注射培美曲塞500 mg·m-2,顺铂70 mg·m-2。试验主要终点为客观缓解率(ORR),次要终点为无疾病进展期(PFS)、总生存期(OS)和毒性。采用Kaplan-Meier法计算生存率。结果:患者客观响应率为65.4%(95%CI:50.3%-78.1%),42例患者有部分缓解,11例患者疾病稳定。PFS和OS分别为7.1(95%CI:6.3-8.7)个月与15.5个月(95%CI:11.5-19.5)个月。29.2%的患者出现3级或4级嗜中性白血球减少症,无发热性中性粒细胞减少情况出现。结论:培美曲塞联合顺铂用于晚期尿路上皮癌一线治疗十分有效,且耐受性良好。

The Efficacy and Safety of Pemetrexed plus Cisplatin on Patients with Advanced Urothelial Carcinoma

Objective:To evaluate the efficacy and safety of patients with advanced urothelial carcinoma treated by pemetrexed plus cisplatin.Methods:A total of 65 patients with advanced epithelial cancer in our hospital were included. The patients were injected with 500 mg·m-2 pemetrexed and 70 mg·m-2 cisplatin at every fouth week. The primary endpoint for the trial objective was response rate (ORR). The secondary endpoint were progression-free (PFS), overall survival (OS) and toxicity. Survival rate was calculated using the Kaplan-Meier method.Results:The objective response rate of patients was 65.4%(95%CI: 50.3%-78.1%). Fourty-two patients had partial remission, and 11 patients had disease stable. The PFS and OS were respectively 7.1 months (95% CI: 6.3-8.7) and 15.5 months (95%CI: 11.5-19.5). There were 29.2%of patients with grade 3 or 4 neutropenia disease, and no febrile neutropenia situation appeared.Conclusion:Pemetrexed in combination with cisplatin is very effective and well tolerated in the first-line treatment of advanced urothelial cancer.